
NAD+
NAD+ precursor. Reviewed across preclinical mitochondrial-bioenergetic and metabolic models.[1]
PayPal or cash on collection · UK 18+ verification at checkout · For laboratory research use only
Selected research · NAD+
- [1]Mechanistic review of NAD+ precursors NMN and NR across preclinical models and emerging clinical trials.Yoshino J, Baur JA, Imai SI. (2018). NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. Cell Metabolism.PMID 29249689 →
All references describe published research on the compound. They do not constitute clinical guidance or imply therapeutic benefit to any individual purchaser. For laboratory research use only.
Frequently bought together
Full catalogue →MOTS-C
Mitochondrial-derived peptide. Studied in preclinical research on AMPK activation and metabolic-regulation pathways.
From £75.00
5-Amino-1MQ
NNMT inhibitor. Studied in preclinical research on cellular energy-metabolism regulation.
From £75.00
GHK-Cu
Copper peptide naturally occurring in plasma. Studied in preclinical research on skin remodelling, wound-repair pathways, and gene-expression modulation. Referenced in cellular-senescence research groupings.
From £30.00
5-Amino-1MQ Capsules
NNMT inhibitor researched for regulating cellular energy metabolism, supplied in an oral research-format capsule. 100mg per capsule.
From £65.00
Often stacked with NAD+
Full catalogue →Epitalon
Synthetic tetrapeptide. Studied in preclinical research on telomerase activation and pineal-gland function. Referenced in cellular-senescence research.
SS-31 (Elamipretide)
Mitochondria-targeted peptide. Studied in preclinical research on inner-mitochondrial-membrane stabilisation and cellular-energy endpoints.
MOTS-C
Mitochondrial-derived peptide. Studied in preclinical research on AMPK activation and metabolic-regulation pathways.
